Targeting cervical cancer with anti-PD-1 antibodies: what is new?

被引：0
|
作者：
Greenman, Michelle [1 ]
Mcnamara, Blair [1 ]
Mutlu, Levent [1 ]
Santin, Alessandro D. [1 ,2 ]
机构：
[1] Yale Univ, Dept Obstet Gynecol & Reprod Sci, Sch Med, New Haven, CT USA
[2] Yale Univ, Obstet & Gynecol, Sch Med, 333 Cedar St, New Haven, CT 06520 USA
来源：
EXPERT OPINION ON BIOLOGICAL THERAPY | 2024年 / 24卷 / 03期
关键词：
cervical cancer; gynecologic malignancy; PD-1;
D O I：
10.1080/14712598.2024.2323596
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：111 / 114
页数：4
相关论文
共 50 条
  • [21] Anti-PD-1 antibodies therapeutic use in lymphoid neoplasms
    Bounaix, Laura
    Bendouda, Mohammed
    Bay, Jacques-Olivier
    Lemal, Richard
    BULLETIN DU CANCER, 2016, 103 : S160 - S163
  • [22] ANTI PD-1 ANTIBODIES IN RECURRENT METASTATIC CERVICAL AND OVARIAN CANCER
    Perri, T.
    Shapira-Frommer, R.
    Ben-Baruch, G.
    Kalfon, S.
    Beiner, E. M.
    Korach, J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 430 - 430
  • [23] ANTI-PD-1 PLUS A VEGFR2 INHIBITOR SHOWS PROMISE IN CERVICAL CANCER
    不详
    CANCER DISCOVERY, 2020, 10 (12) : 1788 - 1788
  • [24] Bispecific antibodies with an anti-PD-1 backbone for cancer therapy generate enhanced immune activity
    Li, Baiyong
    Huang, Zhaoliang
    Pang, Xinghua
    Zhong, Tingting
    Chen, Na
    Wang, Max
    Jin, Xiaoping
    Xia, Dennis
    Zhang, Peng
    Xia, Michelle Yu
    CANCER RESEARCH, 2018, 78 (13)
  • [25] Anti-tumor effects of lenvatinib plus anti-PD-1 in syngeneic murine cervical cancer models
    Park, Su-Bin
    Kang, Ji-Sik
    Kim, Min-Je
    Lee, Shin-Wha
    Kang, Dong-Woo
    Kim, Yong-Man
    CANCER RESEARCH, 2022, 82 (12)
  • [26] Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies
    Sibaud, Vincent
    Meyer, Nicolas
    Lamant, Laurence
    Vigarios, Emmanuelle
    Mazieres, Julien
    Delord, Jean Pierre
    CURRENT OPINION IN ONCOLOGY, 2016, 28 (04) : 254 - 263
  • [27] Anti-PD-1 monoclonal antibody Cancer immunotherapy
    da Silva, R. Moreira
    DRUGS OF THE FUTURE, 2014, 39 (01) : 15 - 24
  • [28] Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy
    Valecha, Gautam Kishore
    Vennepureddy, Adarsh
    Ibrahim, Uroosa
    Safa, Firas
    Samra, Bachar
    Atallah, Jean Paul
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (01) : 47 - 59
  • [29] Evolving cancer resistance to anti-PD-1/PD-L1 antibodies in melanoma: Comprehensive insights with future prospects
    Li, Wenyu
    Gu, Junjie
    Fan, Hongwei
    Zhang, Li
    Guo, Jun
    Si, Lu
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 201
  • [30] Dosage of anti-PD-1 monoclonal antibodies: a cardinal open question
    Sureda, M.
    Calvo, E.
    Mata, J. J.
    Escudero-Ortiz, V.
    Martinez-Navarro, E.
    Catalan, A.
    Rebollo, J.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23 (08): : 1511 - 1519
12345